The Role Of Trypsin In T Cell Receptor Expression In Pancreatic Cancer

Objective: 1.Immunological disorders in patients with pancreatic cancer;2.The relationship between trypsin and pancreatic cancer;3.Verify in vitro that trypsin affects TCR expression.Methods: 1.Blood sample collectionA total of 103 blood samples of pancreatic cancer were collected from December 2015 to December 2017 and were admitted to the First Affiliated Hospital of Fujian Medical University for surgical resection and confirmed by pathology.All pancreatic cancer patients collected in this study were not subjected to chemotherapy,radiotherapy,or molecular targeting before surgery.2.Blood routine data collection before admission.The lymphocyte counts in the blood routine were collected from 103 patients with pancreatic cancer and 368 normal controls.Counts of lymphocytes in the blood.3.Detection of trypsin prss 1 expression in pancreatic cancer patients.Blood samples of 103 patients with pancreatic cancer and 369 normal controls were placed in a-80 degree refrigerator to extract DNA,PCR amplification,sequencing,and serum trypsin concentration were measured by ELISA.4.The expression of TCRVβ genotypes in pancreatic cancer cell lines overexpressing pancreatic PRSS1,animal models and control,and pancreatic cancer cell lines(normal expression of PRSS1)were detected.5.The expression of CD antigen,interleukin,and MAPK in pancreatic cancer cell line with pancreatic cancer cell over-expressed by trypsin PRSS1 and control was detected.6.Experimental data statisticsAll the data obtained from the experiments in this project were entered into the SPSS 19.0 software one by one,and all the data were checked and confirmed for many times.After accurate verification,all data were systematically analyzed.The χ2 test was used to analyze the expression of trypsin PRSS1 in pancreatic cancer patients with different genotypes and different stages.There was a correlation with the clinicopathological parameters of pancreatic cancer patients.The Kaplan-Meier method and log-rank test were used to draw the pancreas gradually.Survival curves of cancer patients were analyzed and their statistical differences were analyzed.The COX regression multivariate analysis method was used to screen the clinicopathological parameters of all related pancreatic cancers,and related prognostic parameters and possible independent prognostic factors were selected.The T-test was used to analyze the expression of trypsin PRSS1 over-expressed lymphocyte counts,TCRVβ cell lines,and mouse models.All hypothesis tests in the statistical analysis process were conducted using a two-sided test,P<0.05,and were considered statistically significant.Results: 1.Compared with the normal population,PRSS1 is highly expressed in patients with pancreatic cancer;the expression of PRSS1 in patients with different stages of pancreatic cancer is statistically significant;PRSS1 is associated with the clinical stage and survival of patients with pancreatic cancer.2.The pancreatic cancer patients had lower lymphocyte counts compared with normal physical examination patients.The difference was statistically significant.3.There is a correlation between trypsin PRSS1 and the progression of pancreatic cancer.There was no significant correlation with the patient’s age,gender,tumor location,tumor size,differentiation,and whether there was a nerve invasion,but it was significantly related to lymph node metastasis or clinical stage.4.Trypsin PRSS1 may be a biological indicator of the prognosis of pancreatic cancer.The higher the expression level,the worse the prognosis.5.The expression of CD antigens(CD3D,CD5,CD14,CD27,and CD164)in the pancreatic cancer trypsin PRSS1 overexpressing cell line and the control empty cell group was significantly decreased,IL6 R,IL6ST,IL7,IL7 R,IL8,IL13RA1 The expression of IL13RA2,IL15,and IL-12 was significantly increased and the expression of MAPK(MMP2,MAP2K4,MAP2K5,MAP3K1,MAP3K2,MAP3K4,MAP3K5,MAP3K7,and MAP3K8)was significantly increased.6.Statistical analysis showed that the expression of CD antigen,interleukin and MAPK in pancreatic cancer cell line with over-expression of trypsin PRSS1 and control pancreatic cancer cell line were different,P<0.05,the difference was statistically significant.Conclusions: 1.Compared with the normal population,PRSS1 is highly expressed in patients with pancreatic cancer;PRSS1 expression in patients with different stages of pancreatic cancer has a statistically significant difference;PRSS1 and pancreatic cancer patients have clinical stage and survival associated.2.The pancreatic cancer patients had lower lymphocyte counts compared with normal physical examination patients.The difference was statistically significant.3.The presence of trypsin PRSS1 in the progression of disease in patients with pancreatic cancer.There was no significant correlation with the patient’s age,gender,tumor location,tumor size,degree of differentiation,and whether there was a neural invasion.It was significantly associated with lymph node metastasis and clinical stage.4.Trypsin PRSS1 may be a biological indicator of the prognosis of pancreatic cancer.The higher the expression level,the worse the prognosis.5.The expression of TCR Dβ1 in pancreatic cancer cell strain overexpressed by PRSS1,mouse model and control empty pancreatic cancer cell strain and mouse model was different.The expression of Dβ1 in overexpressing cell line and animal model was significantly higher than that in control group.P<0.05,the difference was statistically significant.6.The expression of CD antigen,interleukin and MAPK in PRSS1 overexpressed pancreatic cancer cell lines and control empty cell group were significantly different.Overexpression of PRSS1 may change the microenvironment of cancer cells in pancreatic cancer patients by changing trypsin concentration.Changes,which affect the progression of pancreatic cancer,may affect the development of pancreatic cancer through the regulation of the MAPK pathway.